These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21678208)

  • 1. Reopening old divisions.
    Resnik DB
    Am J Bioeth; 2011 Jun; 11(6):19-21. PubMed ID: 21678208
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimal risk remains an open question.
    Binik A; Weijer C; Sheehan M
    Am J Bioeth; 2011 Jun; 11(6):25-7. PubMed ID: 21678212
    [No Abstract]   [Full Text] [Related]  

  • 3. (Un)risky business: adolescents and HIV prevention trials.
    Philpott S
    Am J Bioeth; 2011 Jun; 11(6):17-9. PubMed ID: 21678207
    [No Abstract]   [Full Text] [Related]  

  • 4. Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.
    Slack CM
    Am J Bioeth; 2011 Jun; 11(6):21-2. PubMed ID: 21678209
    [No Abstract]   [Full Text] [Related]  

  • 5. Uniqueness, exploitation, and relative risk standards in adolescent research.
    Malek J
    Am J Bioeth; 2011 Jun; 11(6):23-5. PubMed ID: 21678211
    [No Abstract]   [Full Text] [Related]  

  • 6. A relative standard for minimal risk is unnecessary and potentially harmful to children: lessons from the Phambili trial.
    Nelson RM
    Am J Bioeth; 2011 Jun; 11(6):14-6. PubMed ID: 21678206
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to Open Peer Commentaries on "Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate".
    Snyder J; Miller CL; Gray G
    Am J Bioeth; 2011 Jun; 11(6):W1-3. PubMed ID: 21678202
    [No Abstract]   [Full Text] [Related]  

  • 8. The dangers of using a relative risk standard for minimal risk.
    Shah S
    Am J Bioeth; 2011 Jun; 11(6):22-3. PubMed ID: 21678210
    [No Abstract]   [Full Text] [Related]  

  • 9. The concept of minimal risk: the need for better guidance on the ethics review process.
    Wada K
    Am J Bioeth; 2011 Jun; 11(6):27-9. PubMed ID: 21678213
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulating "higher risk, no direct benefit" studies in minors.
    Westra AE; Wit JM; Sukhai RN; de Beaufort ID
    Am J Bioeth; 2011 Jun; 11(6):29-31. PubMed ID: 21678214
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate.
    Snyder J; Miller CL; Gray G
    Am J Bioeth; 2011 Jun; 11(6):5-13. PubMed ID: 21678205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trial Design for HIV Prevention Research: Determining Standards of Prevention.
    Dawson L; Zwerski S
    Bioethics; 2015 Jun; 29(5):316-23. PubMed ID: 25230397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can communities protect autonomy? Ethical dilemmas in HIV preventative drug trials.
    Zion D
    Camb Q Healthc Ethics; 1995; 4(4):516-23. PubMed ID: 8563962
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of Zairian children in HIV vaccine experimentation: a cross-cultural study in medical ethics.
    Nairn TA
    Annu Soc Christ Ethics; 1993; ():223-43. PubMed ID: 12568073
    [No Abstract]   [Full Text] [Related]  

  • 15. AIDS vaccine trials in India: ethical benchmarks and unanswered questions.
    Jesani A; Coutinho L
    Indian J Med Ethics; 2007; 4(1):2-3. PubMed ID: 18630210
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV preventive vaccine efficacy trials in the United States: an overview of target communities' concerns.
    Hodel D
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S255-6. PubMed ID: 7865312
    [No Abstract]   [Full Text] [Related]  

  • 17. Unique risks to volunteers in HIV vaccine trials.
    Frey SE
    J Investig Med; 2003 Feb; 51 Suppl 1():S18-20. PubMed ID: 12664950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access to treatment in HIV prevention trials: perspectives from a South African community.
    Barsdorf N; Maman S; Kass N; Slack C
    Dev World Bioeth; 2010 Aug; 10(2):78-87. PubMed ID: 19793135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.
    Temoshok LR
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S277-80. PubMed ID: 7865318
    [No Abstract]   [Full Text] [Related]  

  • 20. Ethics and the standards of prevention in HIV prevention trials.
    Sugarman J; Grace WC
    AIDS; 2010 Sep; 24(14):2298-9; author reply 2299-300. PubMed ID: 20736687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.